SFE Investment Counsel lessened its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 51.8% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,003 shares of the company’s stock after selling 4,301 shares during the period. SFE Investment Counsel’s holdings in Omnicell were worth $324,000 as of its most recent SEC filing.
Several other hedge funds have also modified their holdings of the company. Conestoga Capital Advisors LLC increased its stake in Omnicell by 1.0% during the 1st quarter. Conestoga Capital Advisors LLC now owns 1,546,168 shares of the company’s stock worth $124,992,000 after buying an additional 15,353 shares during the period. Carillon Tower Advisers Inc. grew its holdings in Omnicell by 24.0% during the 1st quarter. Carillon Tower Advisers Inc. now owns 620,512 shares of the company’s stock worth $50,162,000 after acquiring an additional 120,109 shares in the last quarter. Geode Capital Management LLC grew its holdings in Omnicell by 7.9% during the 4th quarter. Geode Capital Management LLC now owns 442,184 shares of the company’s stock worth $27,079,000 after acquiring an additional 32,512 shares in the last quarter. Tributary Capital Management LLC grew its holdings in Omnicell by 1.3% during the 1st quarter. Tributary Capital Management LLC now owns 330,204 shares of the company’s stock worth $26,694,000 after acquiring an additional 4,153 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in Omnicell by 716.6% during the 1st quarter. JPMorgan Chase & Co. now owns 225,620 shares of the company’s stock worth $18,239,000 after acquiring an additional 197,990 shares in the last quarter. 96.35% of the stock is currently owned by institutional investors and hedge funds.
In related news, CFO Peter J. Kuipers sold 1,044 shares of Omnicell stock in a transaction dated Saturday, March 9th. The shares were sold at an average price of $44.34, for a total value of $46,290.96. Following the sale, the chief financial officer now directly owns 56,873 shares in the company, valued at approximately $2,521,748.82. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Randall A. Lipps sold 24,282 shares of the business’s stock in a transaction dated Monday, April 29th. The stock was sold at an average price of $79.01, for a total transaction of $1,918,520.82. The disclosure for this sale can be found here. Over the last quarter, insiders sold 199,464 shares of company stock worth $15,226,091. 2.77% of the stock is currently owned by insiders.
Several research firms have recently commented on OMCL. Zacks Investment Research lowered shares of Omnicell from a “hold” rating to a “sell” rating in a report on Friday, February 15th. Benchmark lifted their price target on shares of Omnicell from $82.00 to $90.00 and gave the company a “buy” rating in a report on Friday, April 26th. BidaskClub lowered shares of Omnicell from a “hold” rating to a “sell” rating in a report on Tuesday, April 23rd. Piper Jaffray Companies reaffirmed a “neutral” rating and issued a $70.00 price target on shares of Omnicell in a report on Friday, February 8th. They noted that the move was a valuation call. Finally, Dougherty & Co lifted their price target on shares of Omnicell from $78.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, March 7th. Five investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $79.89.
NASDAQ:OMCL traded up $1.51 during mid-day trading on Tuesday, hitting $81.76. The stock had a trading volume of 6,196 shares, compared to its average volume of 337,261. The company has a market cap of $3.31 billion, a PE ratio of 53.40, a P/E/G ratio of 2.60 and a beta of 1.20. Omnicell, Inc. has a 52 week low of $45.15 and a 52 week high of $86.87. The company has a quick ratio of 1.47, a current ratio of 1.96 and a debt-to-equity ratio of 0.13.
Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, April 25th. The company reported $0.61 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.23 by $0.38. The firm had revenue of $202.50 million for the quarter, compared to the consensus estimate of $199.72 million. Omnicell had a net margin of 4.74% and a return on equity of 11.10%. Omnicell’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same period last year, the firm posted $0.29 EPS. As a group, equities analysts anticipate that Omnicell, Inc. will post 2.06 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This news story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2019/05/21/omnicell-inc-omcl-holdings-trimmed-by-sfe-investment-counsel.html.
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Featured Article: Cash Asset Ratio
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.